These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Vaccines for Prevention of Group B Meningococcal Disease: Not Your Father's Vaccines. Harrison LH Am J Prev Med; 2015 Dec; 49(6 Suppl 4):S345-54. PubMed ID: 26590434 [TBL] [Abstract][Full Text] [Related]
43. Vaccination with a multicomponent meningococcal B vaccine in prevention of disease in adolescents and young adults. Nolan T; O'Ryan M; Wassil J; Abitbol V; Dull P Vaccine; 2015 Aug; 33(36):4437-45. PubMed ID: 26187261 [TBL] [Abstract][Full Text] [Related]
44. History of meningococcal vaccines and their serological correlates of protection. Vipond C; Care R; Feavers IM Vaccine; 2012 May; 30 Suppl 2():B10-7. PubMed ID: 22607894 [TBL] [Abstract][Full Text] [Related]
45. Meningococcal serogroup B infections: a search for a broadly protective vaccine. Vermont CL; van den Dobbelsteen GP Expert Rev Vaccines; 2003 Oct; 2(5):673-81. PubMed ID: 14711328 [TBL] [Abstract][Full Text] [Related]
46. Use of Serogroup B Meningococcal Vaccines in Adolescents and Young Adults: Recommendations of the Advisory Committee on Immunization Practices, 2015. MacNeil JR; Rubin L; Folaranmi T; Ortega-Sanchez IR; Patel M; Martin SW MMWR Morb Mortal Wkly Rep; 2015 Oct; 64(41):1171-6. PubMed ID: 26492381 [TBL] [Abstract][Full Text] [Related]
47. Authors' response: Meningococcal vaccine antigen diversity in global databases. Brehony C; Hill DM; Lucidarme J; Borrow R; Maiden MC Euro Surveill; 2016 Apr; 21(15):. PubMed ID: 27104935 [No Abstract] [Full Text] [Related]
48. The impact of meningococcal serogroup C conjugate vaccine in Scotland. Mooney JD; Christie P; Robertson C; Clarke SC Clin Infect Dis; 2004 Aug; 39(3):349-56. PubMed ID: 15307001 [TBL] [Abstract][Full Text] [Related]
49. Adverse events following immunisation with a meningococcal serogroup B vaccine: report from post-marketing surveillance, Germany, 2013 to 2016. Mentzer D; Oberle D; Keller-Stanislawski B Euro Surveill; 2018 Apr; 23(17):. PubMed ID: 29717697 [TBL] [Abstract][Full Text] [Related]
51. Meningococcal group C disease in Greece during 1993-2006: the impact of an unofficial single-dose vaccination scheme adopted by most paediatricians. Kafetzis DA; Stamboulidis KN; Tzanakaki G; Kourea Kremastinou J; Skevaki CL; Konstantopoulos A; Tsolia M Clin Microbiol Infect; 2007 May; 13(5):550-2. PubMed ID: 17378929 [TBL] [Abstract][Full Text] [Related]
52. Post-marketing safety monitoring of a new group B meningococcal vaccine in New Zealand, 2004-2006. McNicholas A; Galloway Y; Stehr-Green P; Reid S; Radke S; Sexton K; Kieft C; Macdonald C; Neutze J; Drake R; Isaac D; O'Donnell M; Tatley M; Oster P; O'Hallahan J Hum Vaccin; 2007; 3(5):196-204. PubMed ID: 17660718 [TBL] [Abstract][Full Text] [Related]
53. MeNZB vaccine and epidemic control: when do you stop vaccinating? Loring BJ; Turner N; Petousis-Harris H Vaccine; 2008 Nov; 26(47):5899-904. PubMed ID: 18804134 [TBL] [Abstract][Full Text] [Related]
54. Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience. Djingarey MH; Barry R; Bonkoungou M; Tiendrebeogo S; Sebgo R; Kandolo D; Lingani C; Preziosi MP; Zuber PL; Perea W; Hugonnet S; Dellepiane de Rey Tolve N; Tevi-Benissan C; Clark TA; Mayer LW; Novak R; Messonier NE; Berlier M; Toboe D; Nshimirimana D; Mihigo R; Aguado T; Diomandé F; Kristiansen PA; Caugant DA; Laforce FM Vaccine; 2012 May; 30 Suppl 2():B40-5. PubMed ID: 22607898 [TBL] [Abstract][Full Text] [Related]
55. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers. McVernon J; Nolan T; Richmond P; Reynolds G; Nissen M; Lambert SB; Marshall H; Papa T; Rehm C Pediatr Infect Dis J; 2012 Jan; 31(1):e15-23. PubMed ID: 22094636 [TBL] [Abstract][Full Text] [Related]
56. Meningococcal C vaccines: the Canadian experience. De Wals P Pediatr Infect Dis J; 2004 Dec; 23(12 Suppl):S280-4. PubMed ID: 15597070 [TBL] [Abstract][Full Text] [Related]
57. Meningococcal disease among United States military service members in relation to routine uses of vaccines with different serogroup-specific components, 1964-1998. Brundage JF; Ryan MA; Feighner BH; Erdtmann FJ Clin Infect Dis; 2002 Dec; 35(11):1376-81. PubMed ID: 12439801 [TBL] [Abstract][Full Text] [Related]
58. [Prevention of serogroup B meningococcal disease using a four-component vaccine]. Gil A; Barranco D; Batalla J; Bayas JM; Campins M; Gorrotxategi Gorrotxategi P; Lluch J; Martinón-Torres F; Mellado MJ; Moreno-Pérez D; Uriel B; Vázquez JA An Pediatr (Barc); 2014 Apr; 80(4):259.e1-23. PubMed ID: 24119683 [TBL] [Abstract][Full Text] [Related]
59. Commentary: European Medicines Agency recommends approval of a broadly protective vaccine against serogroup B meningococcal disease. Granoff DM Pediatr Infect Dis J; 2013 Apr; 32(4):372-3. PubMed ID: 23263177 [No Abstract] [Full Text] [Related]
60. The introduction of the meningococcal B (MenB) vaccine (Bexsero®) into the national infant immunisation programme--New challenges for public health. Ladhani SN; Campbell H; Parikh SR; Saliba V; Borrow R; Ramsay M J Infect; 2015 Dec; 71(6):611-4. PubMed ID: 26433141 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]